on Theranexus (EPA:ALTHX)
Theranexus releases voting rights and capital information for March 2024
Lyon, April 26, 2024 - Theranexus, a biopharmaceutical company focused on rare neurological diseases, announced the latest statistics concerning the composition of its share capital and its voting rights as of March 31, 2024. According to the regulations of the commercial code and the general regulations of the Financial Markets Authority (AMF), the company has 7,845,124 shares in its capital.
The total number of theoretical voting rights amounts to 8,817,339. This calculation includes all shares with voting rights, even those without active voting rights, in accordance with article 223-11 of the General Regulations of the AMF.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news